Search

Your search keyword '"Presta, Pierangela"' showing total 24 results
Start Over Author "Presta, Pierangela" Publication Year Range Last 3 years
24 results on '"Presta, Pierangela"'

5. The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study.

Author

Bolignano, Davide, Greco, Marta, Presta, Pierangela, Duni, Anila, Zicarelli, Mariateresa, Mercuri, Simone, Pappas, Efthymios, Lakkas, Lampros, Musolino, Michela, Naka, Katerina K., Misiti, Roberta, Foti, Daniela Patrizia, Andreucci, Michele, Coppolino, Giuseppe, and Dounousi, Evangelia

Subjects
CHRONIC kidney failure, DISEASE risk factors, RECEIVER operating characteristic curves, PEPTIDES, HEMODIALYSIS patients
Abstract

Introduction: Uremic patients exhibit remarkably increased rates of mortality and cardiovascular (CV) events, but risk prediction in this setting remains difficult. Systemic mitochondrial dysfunction is pervasive in end-stage kidney disease and may contribute to CV complications. We tested the clinical significance of circulating MOTS-c, a small mitochondrial-derived peptide, as a biomarker for improving mortality and CV risk prediction in hemodialysis (HD) patients. Methods: We conducted a prospective, observational, multicenter study on 94 prevalent HD patients. The study endpoint was a composite of all-cause mortality and non-fatal CV events. The diagnostic and prognostic capacities of predictive models based on cohort-related risk factors were tested before and after the inclusion of MOTS-c. Results: MOTS-c levels were higher in HD patients than in controls (p < 0.001) and even more elevated (p = 0.01) in the 53 individuals experiencing the combined endpoint during follow-up (median duration: 26.5 months). MOTS-c was independently associated with the endpoint at either multivariate logistic (OR 1.020; 95% CI: 1.011–1.109; p = 0.03) or Cox regression analyses (HR 1.004; 95% CI: 1.000–1.025; p = 0.05) and the addition of this biomarker to prognostic models including the other cohort-related risk predictors (age, left ventricular mass, evidence of diastolic dysfunction, diabetes, pulse pressure) significantly improved the calibration, risk variability explanation, discrimination (receiver operating characteristic area under the curve from 0.727 to 0.743; C-index from 0.658 to 0.700), and particularly, the overall reclassification capacity (NRI 15.87%; p = 0.01). Conclusions: In HD patients, the mitochondrial-derived peptide MOTS-c may impart significant information to refine CV risk prediction, beyond cohort-related risk factors. Future investigations are needed to generalize these findings in larger and more heterogeneous cohorts. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Evaluation of arteriovenous fistula for hemodialysis with a new generation digital stethoscope: a pilot study

Author

Presta, Pierangela, primary, Carullo, Nazareno, additional, Armeni, Annarita, additional, Zicarelli, Maria Teresa, additional, Musolino, Michela, additional, Bianco, Maria Giovanna, additional, Chiarella, Salvatore, additional, Andreucci, Michele, additional, Fiorillo, Antonino S., additional, Pullano, Salvatore Andrea, additional, Bolignano, Davide, additional, and Coppolino, Giuseppe, additional

Published
2023
Full Text
View/download PDF

8. Circulating miRNA 122-5p Expression Predicts Mortality and Cardiovascular Events in Chronic Hemodialysis Patients: A Multicentric, Pilot, Prospective Study

Author

Duni, Anila, primary, Greco, Marta, additional, Presta, Pierangela, additional, Arena, Roberta, additional, Pappas, Ethymios, additional, Lakkas, Lampros, additional, Naka, Katerina K., additional, Brunetti, Antonio, additional, Foti, Daniela Patrizia, additional, Andreucci, Michele, additional, Coppolino, Giuseppe, additional, Dounousi, Evangelia, additional, and Bolignano, Davide, additional

Published
2023
Full Text
View/download PDF

10. #3101 LOW CIRCULATING LEVELS OF CARDIO-REGULATORY MIRNAS PREDICT WORSE OUTCOMES IN HEMODIALYSIS PATIENTS

Author

Zicarelli, Mariateresa, primary, Greco, Marta, additional, Presta, Pierangela, additional, Duni, Anila, additional, Vita, Caterina, additional, Pappas, Efthymios, additional, Mirabelli, Maria, additional, Lakkas, Lampros, additional, Naka, Katerina, additional, Brunetti, Antonio, additional, Foti, Daniela, additional, Andreucci, Michele, additional, Coppolino, Giuseppe, additional, Ntounousi, Evangelia, additional, and Bolignano, Davide, additional

Published
2023
Full Text
View/download PDF

12. A small circulating miRNAs signature predicts mortality and adverse cardiovascular outcomes in chronic hemodialysis patients

Author

Bolignano, Davide, primary, Greco, Marta, additional, Presta, Pierangela, additional, Duni, Anila, additional, Vita, Caterina, additional, Pappas, Ethymios, additional, Mirabelli, Maria, additional, Lakkas, Lampros, additional, Naka, Katerina K, additional, Brunetti, Antonio, additional, Foti, Daniela Patrizia, additional, Andreucci, Michele, additional, Coppolino, Giuseppe, additional, and Dounousi, Evangelia, additional

Published
2023
Full Text
View/download PDF

13. 1087 QUANTITATIVE CHANGES IN INTRACARDIAC FLOW PARAMETERS DURING HEMODIALYTIC SESSIONS

Author

Rosa Romano, Letizia, primary, Sabatino, Jolanda, additional, Calvelli, Pierangelo, additional, Bolignano, Davide, additional, Coppolino, Giuseppe, additional, Presta, Pierangela, additional, Strangio, Antonio, additional, Leo, Isabella, additional, Maglione, Marco, additional, Troilo, Fabio, additional, Loliva, Giuseppe, additional, Critelli, Claudia, additional, Andreucci, Michele, additional, Salvo, Giovanni Di, additional, Indolfi, Ciro, additional, and Rosa, Salvatore De, additional

Published
2022
Full Text
View/download PDF

14. Acquisition of optical coherence tomography angiography metrics during hemodialysis procedures: A pilot study

Author

Coppolino, Giuseppe, primary, Bolignano, Davide, additional, Presta, Pierangela, additional, Ferrari, Fausto Francesco, additional, Lionetti, Giovanna, additional, Borselli, Massimiliano, additional, Randazzo, Giorgio, additional, Andreucci, Michele, additional, Bonelli, Angelica, additional, Errante, Antonietta, additional, Campo, Leonardo, additional, Mauro, Davide, additional, Tripodi, Sarah, additional, Rejdak, Robert, additional, Toro, Mario Damiano, additional, Scorcia, Vincenzo, additional, and Carnevali, Adriano, additional

Published
2022
Full Text
View/download PDF

16. Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy

Author

Bolignano, Davide, primary, Greco, Marta, additional, Arcidiacono, Valentina, additional, Presta, Pierangela, additional, Caglioti, Alfredo, additional, Andreucci, Michele, additional, Dragone, Francesco, additional, Foti, Daniela Patrizia, additional, and Coppolino, Giuseppe, additional

Published
2022
Full Text
View/download PDF

17. Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health

Author

Bellone, Federica, primary, Cinquegrani, Maria, additional, Nicotera, Ramona, additional, Carullo, Nazareno, additional, Casarella, Alessandro, additional, Presta, Pierangela, additional, Andreucci, Michele, additional, Squadrito, Giovanni, additional, Mandraffino, Giuseppe, additional, Prunestì, Marcello, additional, Vocca, Cristina, additional, De Sarro, Giovambattista, additional, Bolignano, Davide, additional, and Coppolino, Giuseppe, additional

Published
2022
Full Text
View/download PDF

18. MO746: Marinobufagenin, Left Ventricular Geometry and Cardiac Dysfunction in End-Stage Kidney Disease Patients

Author

Patella, Gemma, primary, Presta, Pierangela, additional, De Rosa, Salvatore, additional, Greco, Marta, additional, Crugliano, Giuseppina, additional, Sabatino, Jolanda, additional, Cianfrone, Paola, additional, Andreucci, Michele, additional, Indolfi, Ciro, additional, Foti, Daniela, additional, Coppolino, Giuseppe, additional, and Bolignano, Davide, additional

Published
2022
Full Text
View/download PDF

19. MO732: Circulating Omentin-1 and Subclinical Atherosclerosis in Chronic Haemodialysis Patients: A Pilot Study

Author

Presta, Pierangela, primary, Bolignano, Davide, additional, Coppolino, Giuseppe, additional, Crugliano, Giuseppina, additional, Arena, Roberta, additional, Ruosi, Federico, additional, Tripodi, Loredana, additional, Carullo, Nazareno, additional, Zicarelli, Mariateresa, additional, Comi, Alessandro, additional, Comi, Nicolino, additional, Cianfrone, Paola, additional, and Andreucci, Michele, additional

Published
2022
Full Text
View/download PDF

20. MO753: Marinobufagenin Predicts Intradialytic Hypotension Episodes in Prevalent Haemodialysis Patients

Author

Carullo, Nazareno, primary, Greco, Marta, additional, Presta, Pierangela, additional, De Rosa, Salvatore, additional, Crugliano, Giuseppina, additional, Sabatino, Jolanda, additional, Arena, Roberta, additional, Andreucci, Michele, additional, Indolfi, Ciro, additional, Foti, Daniela, additional, Coppolino, Giuseppe, additional, and Bolignano, Davide, additional

Published
2022
Full Text
View/download PDF

21. Nephrosclerosis impacts time trajectory of renal function and outcomes in elderly individuals with chronic kidney disease

Author

Zicarelli, Maria Teresa, primary, Patella, Gemma, additional, Bolignano, Davide, additional, Comi, Alessandro, additional, Cianfrone, Paola, additional, Comi, Nicolino, additional, Presta, Pierangela, additional, Fuiano, Giorgio, additional, Castagna, Alberto, additional, Ruotolo, Giovanni, additional, Andreucci, Michele, additional, and Coppolino, Giuseppe, additional

Published
2021
Full Text
View/download PDF

22. Circulating Omentin-1 levels and altered iron balance in chronic haemodialysis patients

Author

Bolignano, Davide, primary, Dounousi, Evangelia, additional, Presta, Pierangela, additional, Greco, Marta, additional, Duni, Anila, additional, Crugliano, Giuseppina, additional, Pappas, Charalambos, additional, Pappas, Ethymios, additional, Dragone, Francesco, additional, Lakkas, Lampros, additional, Foti, Daniela Patrizia, additional, Andreucci, Michele, additional, and Coppolino, Giuseppe, additional

Published
2021
Full Text
View/download PDF

23. Autosomic dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease.

Author

Casarella, Alessandro, Nicotera, Ramona, Zicarelli, Maria T., Urso, Alessandra, Presta, Pierangela, Deodato, Francesca, Bolignano, Davide, De Sarro, Giovambattista, Andreucci, Michele, Russo, Emilio, and Coppolino, Giuseppe

Subjects
TYPE 2 diabetes, POLYCYSTIC kidney disease, CONGENITAL disorders, CHRONIC kidney failure, METFORMIN, CYSTIC kidney disease
Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common congenital kidney disorder, generally caused by mutations in the PKD1 and PKD2 genes, coding for polycystins 1 and 2. Its pathogenesis is accompanied by alterations of the cAMP, mTOR, MAPK/ERK, and JAK/STAT pathways. ADPKD is clinically characterized by the formation of many growing cysts with kidney enlargement and a progressive damage to the parenchyma, up to its complete loss of function, and the onset of end‐stage renal disease (ESRD). The current aim of ADPKD therapy is the inhibition of cyst development and retardation of chronic kidney disease progression. Several drugs have been recently included as potential therapies for ADPKD including metformin, the drug of choice for the treatment of type 2 diabetes mellitus, according to its potential inhibitory effects on cystogenesis. In this review, we summarize preclinical and clinical evidence endorsing or rejecting metformin administration in ADPKD evolution and pathological mechanisms. We explored the biology of APDKD and the role of metformin in slowing down cystogenesis searching PubMed and Clinical Trials to identify relevant data from the database inception to December 2020. From our research analysis, evidence for metformin as emerging cure for ADPKD mainly arise from preclinical studies. In fact, clinical studies are still scanty and stronger evidence is awaited. Its effects are likely mediated by inhibition of the ERK pathway and increase of AMPK levels, which are both linked to ADPKD pathogenesis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. Altered circulating marinobufagenin levels and recurrent intradialytic hypotensive episodes in chronic hemodialysis patients: a pilot, prospective study.

Author

Bolignano, Davide, Greco, Marta, Presta, Pierangela, Crugliano, Giuseppina, Sabatino, Jolanda, Carullo, Nazareno, Arena, Roberta, Leo, Isabella, Comi, Alessandro, Andreucci, Michele, Dragone, Francesco, Strangio, Antonio, Indolfi, Ciro, Foti, Daniela Patrizia, De Rosa, Salvatore, and Coppolino, Giuseppe

Subjects
CHRONIC kidney failure, STEROIDS, HYPOTENSION, HEMODIALYSIS, LONGITUDINAL method
Abstract

Intradialytic hypotension (IDH) is a sudden and often serious complication of chronic hemodialysis (HD). In this prospective study, we aimed at evaluating the clinical predictors of IDH in a homogeneous cohort of chronic HD patients, with a particular focus on marinobufagenin (MBG), an endogenous cardiotonic steroid which alterations have previously been involved in various cardiovascular disorders. MBG levels in HD patients were significantly higher than in controls (p = 0.03), remained unchanged throughout a single HD session and were not correlated with the absolute or partial fluid loss achieved. During a 30-day follow-up, 19 patients (65.5%) experienced at least one IDH (73 total episodes). An inverse correlation was found between baseline MBG and the number of IDH (R = -0.55; p = 0.001). HD patients experiencing IDH presented remarkably lower baseline MBG as compared to others (p = 0.008) with a statistically significant trend during HD (p = 0.02). At Kaplan-Meier analyses, HD patients with lower MBG manifested a four-to-six fold increased risk of IDH during follow-up (crude Hazard Ratio ranging from 4.37 to 6.68). At Cox regression analyses, MBG measurement at different time points resulted the strongest time-dependent predictors of IDH among all the variables considered (HR ranging from 0.068 to 0.155; p: 0.002 to <0.0001). Findings obtained suggest that differently altered MBG in chronic HD patients may reflect a diverse vascular and hemodynamic tolerance to HD stress, eventually leading to recurrent IDH episodes. Further studies are needed to confirm the prognostic capacity of MBG for identifying HD patients at high risk of IDH, particularly those with apparently optimal fluid status. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results